Jubilant Pharmova Ltd.
Snapshot View

View in App

Prices View details

412.00 +12.15 ▲3.0%

20 May 2022, 04:01:00 PM
Volume: 7,171

Overview View Details

Sector Healthcare Compare with Sector peers
Industry Pharmaceuticals & Drugs Compare with Industry peers
Website http://www.jubilantpharmova.com
Market Cap 6,498.67 Cr.
Enterprise Value(EV) 8,411.83 Cr. 2021-09
Financial Indicators
Earnings per share (EPS) 35.68 Trailing Twelve Months Ending 2021-12
Price-Earning Ratio (PE) 11.55 Trailing Twelve Months Ending 2021-12
Industry PE 29.26 Trailing Twelve Months Ending 2021-12
Book Value / Share 323.91 Trailing Twelve Months Ending 2021-12
Price to Book Value 1.27 Calculated using Price: 412.00
Dividend Yield 1.23 Period Ending 2021-03
No. of Shares Subscribed 15.93 Cr. 159,281,139 Shares
FaceValue 1
Company Profile

Jubilant Life Sciences (formerly Jubilant Organosys) was incorporated in the year 1978. It’s a public limited company domiciled in India and incorporated under the provisions of Companies Act, 1956. Its shares are listed on BSE Limited and National Stock Exchange of India Limited.

The Pharmaceuticals segment, through its wholly-owned subsidiary Jubilant Pharma Limited, is engaged in manufacturing and supply of APIs, solid dosage formulations, radiopharmaceuticals, allergy therapy products and contract manufacturing of sterile injectables and non-sterile products through six USFDA approved manufacturing facilities in the US, Canada and India and a network of various radiopharmacies in the US.

The Life Science Ingredients segment is engaged in specialty intermediates, nutritional products and life science chemicals through five manufacturing facilities in India. The drug discovery solutions business is served by Jubilant Biosys and the India branded pharmaceuticals business is an Indian venture with a range of pharmaceutical offerings for the domestic market, focusing primarily on products to treat medical conditions in the field of cardiology and diabetology.

Business area of the company

Jubilant Life Sciences is an integrated global pharmaceutical and life sciences company engaged in pharmaceuticals, life science ingredients, drug discovery solutions and India branded pharmaceuticals.

Business segments

  • Pharmaceuticals
  • Life Science Ingredients
  • Drug Discovery & Development Solutions
  • India Branded Pharmaceuticals

Awards

2012

  • NDTV Profit Business Leadership Award 2012 for Corporate Social Responsibility. National Quality Excellence Award for best in Class manufacturing presented by Stars of the Industry Group.CII ‘National Award for Excellence in Water Management 2012’ as ‘Water Efficient Unit’ for Gajraula Unit.
  • Economic Times - Frost & Sullivan India Manufacturing Excellence Gold Award - Process Sector for 2012. I.C.C. Award for Water Resource Management in Chemical Industry for the year 2011.

2013

  • Jubilant Life Sciences Awarded ‘Excellence Award’ by Export Promotion Bureau.
  • Jubilant Life Sciences declared winner of ‘Supply Chain Excellence Awards’ at 7th Express, Logistics & Supply Chain Leadership Awards 2013.
  • Jubilant Life Sciences receives prestigious NDTV Profit Business Leadership Award 2012 for Corporate ‘Social Responsibility’.

2014

  • Jubilant Life Sciences wins Excellence Awards at ‘India Pharma Awards’ 2014.
  • BRI Partners with Jubilant Life Sciences to Bring XylamaxTM to the South Asia Poultry Market.
  • Jubilant Life Sciences conferred with Golden Peacock Business Excellence Award-2014.
  • Jubilant Biosys and Orion Corporation Announces Unique Collaborative Discovery Program in Pain Management Area.
  • IDRI and Jubilant Chemsys Extend Research for TB Drug Discovery.
  • Jubilant Life Sciences declared winner of 'Bio Excellence Award 2014' at Bangalore India Bio 2014.
  • Jubilant Biosys Announces Expansion of Drug Discovery Alliance with Janssen Pharmaceutical.

2015

  • Jubilant Life Sciences conferred with Golden Peacock National Quality Award.
  • Jubilant Life Sciences wins ASSOCHAM’s ‘Responsible Organization Excellence’ Award 2014-15.

2016

  • Sustainability Award for Best Green Process in ‘Chemical Sector’ by ‘FICCI Chemicals & Petrochemicals Awards, 2016’.
  • Winner of two CHEMEXCIL Export Awards: Trishul Export Award 2012-13 and Gold Export Award 2011-12.
  • 16th Annual Greentech Environment Award 2015 (Gold Category), conferred under ‘Chemicals and Pharmaceutical sector’ - Gajraula plant, India.

2017

  • Social Entrepreneur of the Year (SEOY)-India Award 2017.
  • Finalists for Social Entrepreneur of the Year (SEOY) India 2017 Award.
  • ‘Second Awards’ under the category of Basic Inorganic, Organic Chemicals including Agro Chemicals for the outstanding export performance of the year 2015-16 by CHEMEXCIL.

Delivery View Details

Delivered Qty
Traded Qty

Performance View Details

1 Day
+3.04%
1 Week
+3.43%
1 Month
-13.76%
3 Month
-7.27%
6 Month
-32.50%
1 Year
-51.40%
2 Year
-9.97%
5 Year
-41.54%
10 Year
+122.64%

Ratios View Details

9 years 2013-03 2014-03 2015-03 2016-03 2017-03 2018-03 2019-03 2020-03 2021-03
Return on Equity (%) 7.98 5.39 -1.58 14.27 17.95 16.87 12.97 17.25 15.94
Return on Capital Employed (%) 10.19 7.92 5.72 12.42 14.44 15.21 13.06 15.07 16.49
Return on Assets (%) 2.34 1.60 -0.46 4.46 6.52 6.91 5.55 7.60 7.82

Balance Sheet View Details

Particulars 10 years 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2021-09* Rs. Cr.
Shh. Funds 2,476 2,627 2,454 2,966 3,436 4,087 4,809 5,604 4,741 5,109
Non Curr. Liab. 3,005 2,185 4,036 3,347 3,826 3,417 4,420 4,088 2,973 3,070
Curr. Liab. 2,778 3,894 2,129 2,464 1,684 2,005 2,090 2,619 1,049 1,160
Minority Int. 112 158 -38 -47 -52 0 0 0
Equity & Liab. 8,371 8,864 8,619 8,740 8,899 9,457 11,319 12,310 8,763 9,338
Non Curr. Assets 5,810 5,936 5,904 5,864 5,951 6,267 6,734 7,272 5,811 6,077
Curr. Assets 2,561 2,928 2,715 2,875 2,948 3,190 4,585 5,038 2,953 3,261
Misc. Exp. not W/O
Total Assets 8,371 8,864 8,619 8,740 8,899 9,457 11,319 12,310 8,763 9,338

Profit Loss View Details

Particulars 10 years 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2021-12 Rs. Cr. TTM
Net Sales 5,166 5,803 5,826 5,749 5,861 7,518 9,111 9,154 8,906 6,182
Other Income 30 19 42 13 25 40 36 47 30 21
Total Income 5,196 5,822 5,869 5,763 5,886 7,558 9,147 9,202 8,935 6,203
Total Expenditure -4,098 -4,782 -5,125 -4,502 -4,516 -5,999 -7,372 -7,207 -7,014 -4,899
PBIDT 1,098 1,040 744 1,260 1,370 1,558 1,775 1,995 1,921 1,305
Interest -311 -337 -368 -371 -341 -284 -220 -287 -247 -149
Depreciation -254 -281 -288 -347 -291 -415 -371 -462 -452 -367
Taxation -152 -70 -80 -155 -163 -225 -327 -312 -376 -254
Exceptional Items -192 -214 -48 -280 -35 -21 -10
PAT 189 138 -40 387 575 634 577 898 824 524
Minority Interest -36 -29 -18 5 1 8 -3 0 1
Share Associate 11 3
Other Related Items
Consolidated Net Profit 153 109 -58 392 576 643 574 898 836 568
Adjusted EPS 10 7 -4 25 37 41 36 56 53 36

Cash Flow View Details

Particulars 10 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr.
Cash Fr. Operatn. 707 970 772 783 1,099 1,268 1,303 1,122 1,543 1,784
Cash Fr. Inv. -594 -500 -174 -343 -313 -450 -618 -1,012 -327 -739
Cash Fr. Finan. -889 -450 -414 -503 -843 -686 -901 657 -1,050 -1,709
Net Change -776 20 183 -63 -56 132 -216 767 166 -664
Cash & Cash Eqvt 263 280 473 392 339 456 244 1,005 1,231 502

Shareholding Pattern View Details

9 Qtrs 2020-03 (%) 2020-06 (%) 2020-09 (%) 2020-12 (%) 2021-03 (%) 2021-06 (%) 2021-09 (%) 2021-12 (%) 2022-03 (%)
Promoter 50.68 50.68 50.68 50.68 50.68 50.68 50.68 50.68 50.68
Public 49.32 49.32 49.32 49.32 49.32 49.32 49.33 49.32 49.32
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00

Announcements View Details

Sat, 21 May 2022
Compliances-Reg.24(A)-Annual Secretarial Compliance
Pursuant to the SEBI Circular no. CIR/CFD/CMD1/27/2019 dated February 8 2019 please find enclosed the Annual Secretarial Compliance Report dated May 18 2022 for the financialyear 2021-22. We request you to take the same on record.
Fri, 20 May 2022
Board Meeting Intimation for Intimation Of Board Meeting - May 27 2022
Jubilant Pharmova Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 27/05/2022 inter alia to consider and approve In terms of Regulation 29 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015 (the Listing Regulations) we wish to inform you that a meeting of the Board of Directors of the Company is scheduled to be held on Friday May 27 2022 to inter-alia consider:1. Audited Standalone and Consolidated Financial Results of the Company for the quarter and year ended March 31 2022; and 2. Recommendation of Dividend for the Financial Year ended March 31 2022.This is for information and record.
Fri, 20 May 2022
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015 we wish to inform you that the Company is organising a Conference Call on May 27 2022 after submission of the financial results for the quarter and year ended March 31 2022 to the Stock Exchanges. Details of the Conference Call are attached. This is for information and record.

Technical Scans View Details

Fri, 20 May 2022
Close Within 52 Week Low Zone Close Within 52 Week Low Zone
High Decrease 1 Month High Decrease 1 Month
High Decrease 6 Months High Decrease 6 Months
High Decrease 1 Year High Decrease 1 Year
20 SMA Crossing 50 SMA From Above 20 SMA Crossing 50 SMA From Above

Related Stocks View Details

Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 219,659.12 915.50 +3.5%
Divi's Laboratories Ltd. 114,020.08 4,295.05 +2.2%
Cipla Ltd. 78,954.82 978.60 +4.3%
Dr. Reddy's Laboratories Ltd. 70,669.41 4,246.30 +8.1%
Apollo Hospitals Enterprise Ltd. 52,783.35 3,671.00 +1.0%
Gland Pharma Ltd. 50,388.39 3,061.70 -1.1%
Piramal Enterprises Ltd. 45,754.22 1,917.10 +1.2%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-12 34.09 915.50 +3.5%
Divi's Laboratories Ltd. Consolidated 2021-12 44.40 4,295.05 +2.2%
Cipla Ltd. Consolidated 2022-03 31.37 978.60 +4.3%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 32.38 4,246.30 +8.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-12 46.57 3,671.00 +1.0%
Gland Pharma Ltd. Consolidated 2022-03 41.59 3,061.70 -1.1%
Piramal Enterprises Ltd. Consolidated 2021-12 36.83 1,917.10 +1.2%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-12 4.25 915.50 +3.5%
Divi's Laboratories Ltd. Consolidated 2021-12 10.53 4,295.05 +2.2%
Cipla Ltd. Consolidated 2022-03 3.79 978.60 +4.3%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 3.68 4,246.30 +8.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-12 9.54 3,671.00 +1.0%
Gland Pharma Ltd. Consolidated 2022-03 7.04 3,061.70 -1.1%
Piramal Enterprises Ltd. Consolidated 2021-12 1.29 1,917.10 +1.2%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 0.08 915.50 +3.5%
Divi's Laboratories Ltd. Consolidated 2021-03 0.00 4,295.05 +2.2%
Cipla Ltd. Consolidated 2021-03 0.10 978.60 +4.3%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 0.17 4,246.30 +8.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 0.62 3,671.00 +1.0%
Gland Pharma Ltd. Consolidated 2021-03 0.00 3,061.70 -1.1%
Piramal Enterprises Ltd. Consolidated 2021-03 1.16 1,917.10 +1.2%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 4.98 915.50 +3.5%
Divi's Laboratories Ltd. Consolidated 2021-03 23.90 4,295.05 +2.2%
Cipla Ltd. Consolidated 2021-03 14.13 978.60 +4.3%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 11.53 4,246.30 +8.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 3.44 3,671.00 +1.0%
Gland Pharma Ltd. Consolidated 2021-03 20.97 3,061.70 -1.1%
Piramal Enterprises Ltd. Consolidated 2021-03 3.33 1,917.10 +1.2%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 4.98 915.50 +3.5%
Divi's Laboratories Ltd. Consolidated 2021-03 23.90 4,295.05 +2.2%
Cipla Ltd. Consolidated 2021-03 14.13 978.60 +4.3%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 11.53 4,246.30 +8.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 3.44 3,671.00 +1.0%
Gland Pharma Ltd. Consolidated 2021-03 20.97 3,061.70 -1.1%
Piramal Enterprises Ltd. Consolidated 2021-03 3.33 1,917.10 +1.2%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 33,498.14 915.50 +3.5%
Divi's Laboratories Ltd. Consolidated 2021-03 6,969.40 4,295.05 +2.2%
Cipla Ltd. Consolidated 2021-03 19,159.59 978.60 +4.3%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 19,047.50 4,246.30 +8.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 10,560.00 3,671.00 +1.0%
Gland Pharma Ltd. Consolidated 2021-03 3,462.88 3,061.70 -1.1%
Piramal Enterprises Ltd. Consolidated 2021-03 12,809.35 1,917.10 +1.2%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 2,284.68 915.50 +3.5%
Divi's Laboratories Ltd. Consolidated 2021-03 1,984.29 4,295.05 +2.2%
Cipla Ltd. Consolidated 2021-03 2,401.30 978.60 +4.3%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 1,903.60 4,246.30 +8.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 136.00 3,671.00 +1.0%
Gland Pharma Ltd. Consolidated 2021-03 996.96 3,061.70 -1.1%
Piramal Enterprises Ltd. Consolidated 2021-03 1,074.43 1,917.10 +1.2%